



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10562842
Filing Date	2005-12-29
First Named Inventor	Garcia-Rondenas et al.
Art Unit	1651
Examiner Name	D.K. Ware
Attorney Docket Number	112701-696

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
Dean	1	4476606	US	1985-01-29	Michnowski	
	2	4992420	US	1991-02-12	Jean-Richard	
	3	4994441	US	1991-02-19	Jean-Richard	
	4	5972399	US	1999-10-26	Lapre et al.	
	5	6462029	US	2002-10-08	Eliasz, Isaac	
	6	6706305	US	2004-03-16	Wolt et al.	
Dean	7	6875459	US	2005-04-05	Kopf et al.	

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562842
Filing Date	2005-12-29
First Named Inventor	Garcia-Rodenas et al.
Art Unit	1651
Examiner Name	D.K. Ware
Attorney Docket Number	112701-696

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
<i>DKW</i>	1	20060148754	US	2006-06-06	Pouteau et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
<i>DKW</i>	1	698980 A	SU		1979-11-25			<input type="checkbox"/>
<i>DKW</i>	2	2087531 C1	RU		1997-08-20			<input type="checkbox"/>
<i>DKW</i>	3	98/31239	WO		1998-07-23	Beresteijn et al.		<input type="checkbox"/>
<i>DKW</i>	4	20017622 U	DE		2001-04-12			<input type="checkbox"/>
<i>DKW</i>	5	10117185 A1	DE		2002-10-02			<input type="checkbox"/>
<i>DKW</i>	6	2005/002600 A2	WO		2005-01-13	Garcia-Rodenas et al.		<input type="checkbox"/>
<i>DKW</i>	7	2005/002602 A2	WO		2005-01-13	Pouteau et al.		<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562842
Filing Date	2005-12-29
First Named Inventor	Garcia-Rondenias et al.
Art Unit	1651
Examiner Name	D.K. Ware
Attorney Docket Number	112701-696

<i>DAW</i>	8	2006/029350	EP		2006-03-16	Murphy et al.		<input type="checkbox"/>
------------	---	-------------	----	--	------------	---------------	--	--------------------------

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T5
<i>DAW</i>	1	Simon, J et al., EFFECT OF FASTING, GLUCOSE, AMINO ACIDS AND FOOD INTAKE ON IN VIVO INSULIN RELEASE IN THE CHICKEN, Hormone and Metabolic Research, (March 1978), vol. 10, no. 2, pp. 93-98.	<input type="checkbox"/>
	2	Tuomilehto, Jaakko et al., A DOUBLE-BLIND EVALUATION OF GUAR GUM IN PATIENTS WITH DYSLIPIDAEMIA, Human Nutrition: Clinical Nutrition, (March 1983), vol. 37, no. 2, pp. 109-116.	<input type="checkbox"/>
	3	Bommartini F. et al., GUAR-CAROB BEAN ASSOCIATION IN THE CONTROL OF POST-PRANDIAL HYPERGLYCEMIA, Giornale Di Gerontologia, (1985), vol. 33, no. 6, pp. 497-504.	<input type="checkbox"/>
	4	Casimirri, F. et al., EFFECT OF GUAR ON PLASMA LIPIDS AND ON THE BIOLOGICAL ACTIVITY OF INSULIN IN PATIENTS WITH TYPE 2 DIABETES MELLITUS!, Database Medline Online! US National Library of Medicine (NLM), (15 December 1987), vol. 78, no. 23, pp. 1753-1757.	<input type="checkbox"/>
	5	Liberenti, Maria C., EFFECT OF SOYA AND CELLULOSE FIBERS ON POSTMRANDIAL GLYCEMIC RESPONSE IN TYPE II DIABETIC PATIENTS, Diabetes Care, (1992), vol. 15, no. 1, pp. 111-113.	<input type="checkbox"/>
	6	Feldman, Nira et al., ENRICHMENT OF AN ISRAELI ETHNIC FOOD WITH FIBRES AND THEIR EFFECTS ON THE GLYCAEMIC AND INSULINAEMIC REPNSES IN SUBJECTS WITH NON-INSULIN-DEPENDENT DIABETES MELLITUS, British Journal of Nutrition, (1995), vol. 74, no. 5, pp. 681-688.	<input type="checkbox"/>
	7	Knapper et al., HORMONE AND METABOLIC RESEARCH, (1995), vol. 27, no. 1, pp. 485-490.	<input type="checkbox"/>
<i>DAW</i>	8	Anderson, James W. et al., EFFECTS OF PSYLLIUM ON GLUCOSE AND SERUM LIPID RESPONSES IN MEN WITH TYPE 2 DIABETES AN HYPERCHOLESTEROLEMIA, American Society for Clinical Nutrition, (October 1999), vol. 70, no. 4, pp. 466-473.	<input type="checkbox"/>

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10562842
	Filing Date		2005-12-29
	First Named Inventor	Garcia-Rondenas et al.	
	Art Unit	1651	
	Examiner Name	D.K. Ware	
	Attorney Docket Number	112701-696	

9	Kelly, Gregory S., INSULIN RESISTANCE: LIFESTYLE AND NUTRITIONAL INTERVENTIONS, <i>Alternative Medicine Review</i> , (April 2000), vol. 5, no. 2. pp. 109-132.	<input type="checkbox"/>
10	Konerirajapuram Natarajan Sulochana et al., EFFECT OF ORAL SUPPLEMENTATION OF FREE AMINO ACIDS IN TYPE 2 DIABETIC PATIENTS - A PILOT CLINICAL TRIAL, <i>Medical Science Monitor, Mediscience</i> , (March 2002), vol. 8, no. 3, pp. CR131-CR137.	<input type="checkbox"/>
11	Reid, Robert et al., DIETARY COUNSELLING FOR DYSLIPIDEMIA IN PRIMARY CARE: RESULTS OF A RANDOMIZED TRIAL, (December 21, 2002), vol. 63, no. 4, pp. 169-175.	<input type="checkbox"/>
12	Loon, Luc J.C., AMINO ACID INGESTION STRONGLY ENHANCES INSULIN SECRETION IN PATIENTS WITH LONG-TERM TYPE 2 DIABETES, <i>Diabetes Care</i> , (March 2003), vol. 26, no. 3, pp. 625-630.	<input type="checkbox"/>
13	Belobrajdic D. et al., THE EFFECTS OF DIETARY PROTEIN ON RAT GROWTH, BODY COMPOSITION AND INSULIN SENSITIVITY, (2003), vol. 12, no. SUPPL, pp. S42.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	<i>D. K. Ware</i>	Date Considered	2-12-08
--------------------	-------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10562842
Filing Date	2005-12-29
First Named Inventor	Garcia-Rondenias et al.
Art Unit	1651
Examiner Name	D.K. Ware
Attorney Docket Number	112701-696

CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

☐ That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

☐ That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

☐ See attached certification statement.

☐ Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

☒ None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Robert M. Barrett/	Date (YYYY-MM-DD)	2007-12-10
Name/Print	Robert M. Barrett	Registration Number	30142

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.